<DOC>
	<DOCNO>NCT02510469</DOCNO>
	<brief_summary>The purpose study assess efficacy safety apatinib maintenance therapy adjuvant chemotherapy progressive gastric cancer patient positive exfoliative cancer cell .</brief_summary>
	<brief_title>Apatinib Maintenance Therapy After Adjuvant Chemotherapy Progressive Gastric Cancer With Positive Exfoliative Cancer Cells</brief_title>
	<detailed_description>Eligible patient recieve apatinib treatment ( 500mg qd p.o . q28d ) 6 cycle 8 cycle XELOX adjuvant chemotherapy XELOX adjuvant chemotherapy .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Age : 18 to75 year old ; 2 . ECOG PS 01 ; 3 . Histologically proven gastric cancer stageⅡA , ⅡB , ⅢA , ⅢB ⅢC ( except level 3 4 lymph node high suspicious image confirm biopsy . A minimun 15 examine lymph node recommend ) . All pt receive D2 gastrectomy ; 4 . The exfoliative cancer cell detection peritoneal wash positive ; 5 . Complete 8 cycle XELOX adjuvant chemotherapy recurrence / metastasis occur . No 28 day screen time end chemotherapy ; XELOX : Capectabine 1000mg/m2 po bid d114 , oxaliplatin 130mg/m2 iv d1 , q21d ; 6 . Pts never receive VEGFR inhibitor treatment ( i.e . sorafenib , sunitinib ) ; 7 . Major organ function meet follow criterion : ANC ≥ 1.5 × 109 / L HB ≥ 90g / L PLT ≥ 100 × 109 / L Bilirubin &lt; 1.5 time upper limit normal ( ULN ) ALT AST &lt; 2.5 × ULN 8 . An expected survival ≥ 3 month ; 9 . Pregnancy test ( serum urine ) perform woman childbearing age within 7 day enrolment test result must negative . They shall take appropriate method contraception study 8th week post last administration study drug . For men , ( previous surgical sterilization accept ) , shall agree take appropriate method contraception study 8th week post last administration study drug . 10 . Patient voluntarily join study sign Informed Consent Form study ; 1 . Confirmed apatinib and/or accessory allergy ; 2 . Subjects poorcontrolled arterial hypertension ( systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mm Hg ) despite standard medical management ; Coronary heart disease great ClassII ; IIlevel arrhythmia ( include QT interval prolongation , man ≥ 450 m , woman ≥ 470 m ) together Class II cardiac dysfunction ; 3 . Subjects high gastrointestinal bleeding risk , include follow condition : local active ulcer lesion positive fecal occult blood test ( ++ ) ; history black stool , vomit blood past 2 month ; 4 . Abnormal Coagulation ( INR &gt; 1.5、APTT &gt; 1.5 UNL ) , tendency bleed ; 5 . Factors could effect oral medication ( inability swallow , chronic diarrhea intestinal obstruction ) ; 6 . Associated Peritoneal , liver , CNS ( central nervous system ) distant metastasis ; 7 . Pregnant lactating woman ; 8 . Pts malignant tumor within 5 year ( except cure skin basal cell carcinoma cervical carcinoma ) ; 9 . With psychotropic drug abuse history ca n't get rid mental disorder patient ; 10 . Participated clinical trial within 4 week . 11 . Pts receive VEGFR inhibitor treatment ( i.e . sorafenib , sunitinib ) ; 12 . Any condition might place patient undue risk preclude patient completing study ; 13 . Other condition regiment investigator ' discretion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>